How to Take TUDCA: Dosage, Timing & Side Effects

Most clinical trials have used TUDCA (tauroursodeoxycholic acid) at daily doses between 500 and 1,750 mg, typically split into two or three doses taken with meals. The compound is generally well-tolerated, with diarrhea and mild abdominal discomfort being the most commonly reported side effects. But the “right” dose depends heavily on what you’re taking it for, and the clinical evidence is stronger for some uses than others.

What the Clinical Trials Actually Used

TUDCA dosing in human studies has varied by condition, but a clear pattern emerges across trials. A dose-response study in patients with primary biliary cirrhosis tested 500, 1,000, and 1,500 mg per day for six months. Liver enzyme levels dropped with all three doses, though the two higher doses showed continued improvement over time. The researchers concluded that roughly 10 mg per kilogram of body weight per day was the sweet spot for long-term use.¹ For most adults, that works out to somewhere between 600 and 900 mg daily.

A larger trial in patients with chronic hepatitis compared 250, 500, and 1,000 mg per day against no treatment. All TUDCA doses outperformed the control group, but the 1,000 mg dose produced more improvement than the 250 mg dose, and the two higher doses were the only ones that showed progressive improvement over time. The researchers recommended at least 500 mg daily.² Another trial comparing TUDCA to UDCA (its unconjugated cousin, ursodeoxycholic acid) in primary biliary cholangitis used 250 mg three times daily, totaling 750 mg per day.³

In studies of amyotrophic lateral sclerosis, where TUDCA is being investigated as a neuroprotective agent, the dose threshold for meaningful benefit appears to be at or above 1,000 mg per day. A population-based study found that patients taking 1,000 mg or more daily had better survival outcomes than those on lower doses or no TUDCA at all.⁴ An ongoing phase III trial is testing similar doses across hundreds of patients in Europe.⁵

If you’re taking TUDCA as a general liver support supplement rather than for a specific diagnosed condition, most supplement manufacturers recommend 250 to 500 mg per day. That’s on the lower end of what clinical trials have tested, but it aligns with the dose range that still produced measurable effects on liver enzymes in the chronic hepatitis trial.

Timing, Splitting Doses, and Food

Most clinical trials administered TUDCA in divided doses rather than as a single daily bolus. The typical pattern is two to three doses spread across the day, often with meals. The biliary cholangitis trial, for example, used 250 mg three times daily.³ Splitting the dose makes pharmacological sense because bile acids are absorbed in the gut and undergo enterohepatic circulation, meaning they cycle between the liver and intestines. Taking smaller, more frequent doses keeps TUDCA circulating more evenly throughout the day rather than creating a single spike.

No published trial has directly compared TUDCA taken with food versus on an empty stomach in a head-to-head design. However, because TUDCA is a bile acid and bile secretion ramps up during meals, taking it around mealtimes is a reasonable default. Some people report less stomach discomfort when they take it with food, which tracks with the gastrointestinal side effect profile discussed below. If you’re taking 500 mg or less per day, splitting it into two doses with breakfast and dinner is a practical approach. At higher doses, three times daily with meals mirrors what the clinical trials used.

Side Effects You’re Likely to Encounter

The good news is that TUDCA is one of the better-tolerated bile acid therapies. The bad news is that it can still cause digestive trouble, particularly diarrhea. In the ALS population-based study, about one in five patients reported side effects, with diarrhea being the most common at roughly 14% of patients. Abdominal pain occurred in about 6%, and a small number developed skin reactions. About 8% eventually stopped taking TUDCA because of side effects, and the rest either continued at a lower dose or tolerated the effects.⁴

A trial in progressive multiple sclerosis told a similar story. The most common side effects in the TUDCA group were gastrointestinal: nausea, diarrhea, indigestion, and abdominal cramps. Diarrhea stood out in particular because three participants in the TUDCA group developed it while nobody in the placebo group did. Overall, though, the rate of adverse events didn’t differ significantly between TUDCA and placebo.⁶

No deaths or disease acceleration were observed in TUDCA-treated patients in the ALS study, and the two patients who required hospital visits for adverse events recovered fully after stopping the supplement.⁴ In practice, if TUDCA is going to bother you, it will likely be your gut that objects first. Starting at a lower dose and ramping up over a week or two is a sensible way to test your tolerance before committing to a full clinical dose.

Who Should Be Cautious

People with bile duct obstruction or severe gallbladder disease should avoid TUDCA unless directed by a physician. Because it’s a bile acid, introducing more into a system that can’t properly drain bile could worsen symptoms rather than relieve them. The same caution applies to anyone with a history of cholestatic conditions where bile flow is already compromised.

Pregnancy and breastfeeding data for TUDCA are essentially nonexistent in humans. The clinical trials discussed above enrolled adults with specific conditions and generally excluded pregnant or nursing participants. Without safety data, the default recommendation is to avoid it during pregnancy.

Drug interactions are another area where data is thin but caution makes sense. TUDCA can alter bile acid composition and may affect the absorption of fat-soluble medications and vitamins. If you’re on medications that rely on bile acid metabolism for absorption, or if you’re taking other bile acid therapies like UDCA (ursodiol), check with your prescriber before adding TUDCA. The cystic fibrosis trial at Purdue specifically compared TUDCA with UDCA for effects on bile acid composition and fat-soluble vitamin status, suggesting the interaction between these compounds is clinically relevant.³

Why People Take TUDCA in the First Place

TUDCA’s appeal goes beyond conventional liver support. At the cellular level, it works through at least two distinct protective pathways. The first involves endoplasmic reticulum stress, the cellular equivalent of a factory floor getting backed up. When the ER gets overwhelmed by misfolded proteins, cells activate stress responses that can ultimately trigger self-destruction. TUDCA acts as a chemical chaperone, helping proteins fold correctly and dialing down those stress signals.⁷

The second pathway involves mitochondria, which serve as both the cell’s power plants and its self-destruct switches. When a cell receives signals to die, a protein called Bax punches holes in mitochondrial membranes, releasing molecules that activate the death cascade. TUDCA interferes with this process by preventing Bax from binding to and disrupting mitochondrial membranes.⁸ This prevents the release of cytochrome c, a molecule that sets off the caspase enzymes responsible for dismantling the cell.⁹

These two mechanisms explain why TUDCA keeps appearing in research on conditions as diverse as liver disease, neurodegeneration, and metabolic dysfunction. It’s not that the same molecule treats wildly different diseases through wildly different mechanisms. Rather, ER stress and mitochondrial-driven cell death are common features across many conditions, and TUDCA addresses both.

Insulin Sensitivity and Metabolic Effects

One of the more intriguing findings from human research is TUDCA’s effect on insulin sensitivity. A placebo-controlled trial in obese men and women found that TUDCA treatment improved insulin sensitivity in the liver and muscles by roughly 30%. The improvement was accompanied by measurable changes in insulin signaling at the molecular level in muscle tissue. Adipose tissue, however, didn’t respond the same way.¹⁰

Mouse studies have extended these findings, showing that TUDCA reduces fat accumulation, improves glucose tolerance, and appears to normalize insulin secretion in animals fed high-fat diets.¹¹ These rodent results are promising but shouldn’t be directly extrapolated to humans. The human trial showing the 30% improvement in liver and muscle insulin sensitivity remains the strongest evidence for metabolic benefits, and it was a single study. Whether TUDCA has a meaningful clinical role in managing metabolic syndrome or type 2 diabetes remains an open question that needs larger and longer trials to answer.

Neurological Research and the ALS Connection

TUDCA has drawn serious attention in ALS (amyotrophic lateral sclerosis) research, a field that has had heartbreakingly few treatment breakthroughs. The population-based study described earlier found that patients taking higher-dose TUDCA had a median survival of about 50 months, compared to roughly 36 months in controls. Those on at least 1,000 mg per day showed a substantially reduced risk of death.¹² That’s a retrospective study, not a randomized controlled trial, so the results carry caveats about selection bias and unmeasured confounders. The ongoing phase III TUDCA-ALS trial aims to provide more definitive evidence by enrolling hundreds of patients across Europe in a double-blind, placebo-controlled design.⁵

The biological rationale connects back to the mitochondrial and ER stress pathways already described. Motor neuron death in ALS involves both mitochondrial dysfunction and protein misfolding, which are precisely the processes TUDCA acts on. Research on Alzheimer’s-related cell death has shown similar protective effects, with TUDCA modulating the toxic cascade triggered by amyloid-beta peptides in neurons.¹³ For now, TUDCA is not an approved treatment for any neurological condition, but it’s one of the more closely watched candidates in the pipeline.

Retinal Protection

TUDCA’s protective effects on photoreceptors, the light-sensitive cells in your retina, represent one of the more developed areas of preclinical research. A systematic review of both lab and animal studies concluded that TUDCA effectively delayed retinal neuron degeneration, preserved retinal structure and function, and worked through multiple mechanisms including reducing inflammation, dampening oxidative stress, and suppressing ER stress.¹⁴

In animal models of retinal detachment, TUDCA administration roughly halved the number of dying photoreceptor cells and preserved retinal thickness significantly better than controls.¹⁵ Studies in degenerative retinal models have shown that TUDCA rescues cone photoreceptors specifically by reducing oxidative stress and blocking apoptosis.¹⁶ These results are compelling in the lab, but none of the retinal research has progressed to human clinical trials yet. The doses used in animal studies also involved injection routes, not oral capsules, so it’s unclear whether oral supplementation would deliver enough TUDCA to the retina to matter.

Effects on Gut Bacteria

Because TUDCA is a bile acid that passes through the gut, it inevitably interacts with the microbiome. An animal study found that TUDCA supplementation shifted the relative abundance of certain bacterial genera, boosting some (like Parabacteroides and Mucispirillum) while suppressing others (like Streptococcus). These shifts correlated with improvements in intestinal barrier function.¹⁷

Human data on TUDCA’s microbiome effects is almost nonexistent. A single case report in an elderly woman receiving enteral nutrition found a shift toward Firmicutes dominance in her gut microbiota while on TUDCA, which was unexpected given her age and health status.¹⁸ A single case report with concurrent antibiotic use is about as far from conclusive evidence as you can get, but it does confirm that TUDCA reaches the gut in sufficient quantities to influence bacterial populations. This area is wide open for research, and anyone taking TUDCA long-term is effectively participating in an uncontrolled experiment on their own microbiome.

From Bear Bile to Supplement Capsules

TUDCA’s history stretches back centuries. It occurs naturally in bear bile, which has been used in traditional Chinese medicine for thousands of years to treat liver and gallbladder conditions. The active components of bear bile, primarily UDCA and its taurine-conjugated form TUDCA, were eventually identified and synthesized, making it possible to produce them without involving animals. Synthetic and semi-synthetic production now provides the TUDCA found in both pharmaceutical preparations and dietary supplements.¹⁹

In some countries, TUDCA is available as a prescription pharmaceutical, typically marketed for cholestatic liver diseases. In the United States, it’s sold as a dietary supplement, which means it isn’t subject to the same manufacturing standards or efficacy requirements as prescription drugs. Supplement quality can vary between manufacturers, and the actual TUDCA content of a capsule may not always match what’s on the label. If you’re buying TUDCA as a supplement, look for products that provide third-party testing certificates. The compound itself is well-characterized and stable, but the supplement industry’s quality control is uneven enough that verification matters.

One practical wrinkle worth knowing: TUDCA is the taurine conjugate of UDCA, and the two are sometimes confused or treated as interchangeable. They share some mechanisms, and UDCA (sold as ursodiol) is an established prescription drug for primary biliary cholangitis. But TUDCA is more water-soluble, has somewhat different pharmacokinetics, and in some studies appears to have advantages in cellular protection. They are related molecules, not the same molecule, and swapping one for the other without understanding the difference isn’t advisable if you’re targeting a specific therapeutic effect.